Stockscreener 앱 받기
1.04
0.94%
-0.02
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Releases Corporate Presentation Online - TipRanks
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt
Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus
Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire
Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan
Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia
Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha
Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance
Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo
Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks
Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener
Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan
Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN
What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World
Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN
Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World
Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN
Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World
Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq
H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com
Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus
Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World
Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa
Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com
Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin Biotech Shares Corporate Presentation Update - TipRanks
FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan
Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Moleculin Biotech, Inc. SEC 10-K Report - TradingView
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire
Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - Stock Titan
Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView
0.63%
자본화:
|
볼륨(24시간):